Moreover, ZMYND8 overexpression in doxorubicin-treated cells attenuated the expression of genes (top downregulated) associated with poor prognosis in basal subtype breast cancer patients (Fig. 3c) compared to doxorubicin-downregulated genes (Fig. 3d). The gene discussed is ZMYND8; the disease is breast cancer.